Literature DB >> 8579966

Enzyme and muscle diseases.

M Panteghini1.   

Abstract

Two distinct areas of development contribute to the importance of enzymology in skeletal muscle disease: the measurement of enzymes in serum as a diagnostic aid and the investigation of enzyme deficiencies as the cause of metabolic myopathy. Currently, serum enzyme measurement, particularly creatine kinase, is used to aid in the detection of suspected myopathy, to differentiate myopathy from neurogenic disease, to identify dystrophies at a preclinical stage, to detect female carriers of dystrophies, and to assess response to therapy. Metabolic myopathies are disorders of muscle energy production that result in skeletal muscle dysfunction. The biochemical basis of such disorders is often a specific single enzyme defect. The tremendous advances in the molecular genetics of such disorders has added remarkably to our understanding of the primary defects involved and possible heterogeneity displayed at the molecular level.

Entities:  

Mesh:

Year:  1995        PMID: 8579966     DOI: 10.1097/00002281-199511000-00003

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  6 in total

1.  Performance evaluation of a chemiluminescence microparticle immunoassay for CK-MB.

Authors:  Zhi-Yuan Lin; Yi-Zhen Fang; Hong-Wei Jin; Hua-Yue Lin; Zhang Dai; Qing Luo; Hong-Wei Li; Yan-Ling Lin; Shui-Zhen Huang; Lei Gao; Fei-Hai Xu; Zhong-Ying Zhang
Journal:  J Clin Lab Anal       Date:  2018-03-31       Impact factor: 2.352

Review 2.  An historical approach to the diagnostic biomarkers of acute coronary syndrome.

Authors:  Elisa Danese; Martina Montagnana
Journal:  Ann Transl Med       Date:  2016-05

Review 3.  Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin.

Authors:  Pankaj Garg; Paul Morris; Asma Lina Fazlanie; Sethumadhavan Vijayan; Balazs Dancso; Amardeep Ghosh Dastidar; Sven Plein; Christian Mueller; Philip Haaf
Journal:  Intern Emerg Med       Date:  2017-02-11       Impact factor: 3.397

4.  IFCC Committee on Standardization of Markers of Cardiac Damage: Premises and Project Presentation.

Authors: 
Journal:  EJIFCC       Date:  1999-07-07

Review 5.  Nanoscale Technologies for Prevention and Treatment of Heart Failure: Challenges and Opportunities.

Authors:  Mohammad Javad Hajipour; Mehdi Mehrani; Seyed Hesameddin Abbasi; Ahmad Amin; Seyed Ebrahim Kassaian; Jessica C Garbern; Giulio Caracciolo; Steven Zanganeh; Mitra Chitsazan; Haniyeh Aghaverdi; Seyed Mehdi Kamali Shahri; Aliakbar Ashkarran; Mohammad Raoufi; Holly Bauser-Heaton; Jianyi Zhang; Jochen D Muehlschlegel; Anna Moore; Richard T Lee; Joseph C Wu; Vahid Serpooshan; Morteza Mahmoudi
Journal:  Chem Rev       Date:  2019-09-06       Impact factor: 60.622

6.  Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future.

Authors:  Derek S Sim; Hsiao Lieu; Patrick Andre
Journal:  Biomark Insights       Date:  2008-05-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.